Get started
PACS - Dec 24 100SMA StrongWeak Bounce Sector: Nursing facilities Revenue and EPS has stalled, not clear consistency. Short Interest: 1.98% ADR 5.17% Does it respect the H1 100SMA (Min 3Months): Yes Both founders have around 45M units of stock left after selling in Sep (8M units), Apr (1.6M units) 4 Nov, Hindenburg has done a short report leading to a gap down and decline of almost 60%. hindenburgresearch.com 26 Nov PACS Group receives NYSE non-compliance notice Is it a Hype Thematic (AI, Solar): Potential US healthcare 100SMA StrongWeak Bounce 🏀 (0.5R) v1.0 Trading risk at 0.5R as we are testing this strategy This trade model is based on us riding the 100SMA trend waves of the strongest and weakest companies. It only executes well when greater force (RUT & SPX) is trending. Entries are at greater force key levels when it is consolidating. When greater force is taking off it is too late. Entry Within Stdev 100 zone SL = ATR14 * 2 (Run full course no early exits) Trailing stop (Previous Day Low or high) Price launch off (D1) D2 Closes D3 Move SL to D2 Low
NYSE:PACSShort
by Ronin_trader
MEG - Dec 24 100SMA StrongWeak BounceBet size is 1/2 kelly f*portfolio = (11690/2)*0.5 (I already have PACS running so I accounted for 2 stocks) MEG - Sector: Environmental services & consulting - Past two quarters, revenue and EPS has stalled - ADR 9.56% - Short Interest: 8.07% - Avg Vol (30D): 787.48K - Market cap: 573M - Does it respect the H1 100SMA (Min 3Months): Yes - Is it a Hype Thematic (AI, Solar): No - Nothing from insider filings 100SMA StrongWeak Bounce 🏀 (0.5R) v1.0 Trading risk at 0.5R as we are testing this strategy This trade model is based on us riding the 100SMA trend waves of the strongest and weakest companies. It only executes well when greater force (RUT & SPX) is trending. Entries are at greater force key levels when it is consolidating. When greater force is taking off it is too late. Entry Within Stdev 100 zone SL = Candle open + ATR14 * 2 Trailing stop (Previous Day Low or high) Price launch off (D1) D2 Closes D3 Move SL to D2 Low
NYSE:MEGShort
by Ronin_trader
Comcast Web CastA web of potential zones of influence and 3 curves that might act as support and/or resistance. Looking for consolidations at the elements, breaks, and perhaps one important inflection point at one of them. The main scenario follows the path of the rectangles, but hopefully they are designed well enough so that if the path of the stock price deviates into anything else, we might see a pivot or other developments (: bounce) at the most important of them all which can be either of them depending on the evolutions.
NASDAQ:CMCSA
by nen
SMLT 1H Swing Long Aggressive CounterTrend TradeAggressive CounterTrend Trade - short impulse - unvolumed T1 + support level + volumed 2Sp+ + weak test + biggest volume first buying bar close entry Calculated affordable stop limit 1 to 2 R/R take profit Daily CounterTrend "- short impulse + volumed T1 + support level + volumed manipulation" Monthly Trend "+ long impulse + T2 level + support level + biggest volume manipulation" Yearly trend "+ T1 level + support level + biggest volume manipulation?"
RUS:SMLTLong
by MishaSuvorov
Cloudflare: ResistanceBy expanding the green wave 3, NET recently stretched above the resistance at $117.70. However, the stock only briefly surpassed this level before encountering selling pressure, which pushed it back to its early December levels. Primarily, we expect the price to overcome this resistance to complete the green five-wave structure and, thus, the orange wave iii. A still ongoing wave alt.ii correction remains a possibility in the context of our 30% likely alternative scenario.
NYSE:NET
by MarketIntel
CLEO (VCP - 28W 24/7 3T)Position update: December 20, 2024. Key factors: 1. Low-risk entry point. 2. Confirmed stage 2 uptrend. 3. Has gone through its majority line of supply. 4. Moving on its own drummer, the stock went up +125% while the index remains nowhere. 5. High relative strength. 6. Volume dries up as less supply coming to the market. 7. Both breakouts accompanied with a decent volume. Considerations: The current market environment remains challenging, as it fails to sustain a bullish trend and continues making lower lows. However, this is the only stock that is setting up properly in the current market. This is a quintessential VCP with clear contractions and a defined entry point. I’d like to see if it can hold up and follow through from here.
IDX:CLEOLong
by rifqonr
V.F. Corporation (VFC) (For Study Purpose Only)Entry Price Range: $20 - $22 Stop Loss (SL): $15.35 Portfolio Allocation: 1% of the portfolio Risk Level: High Rationale: Attractive Entry Point: The suggested price range provides a potential value zone in the stock. Risk Management: Strict stop-loss placement at $15.35 limits downside exposure. Portfolio Allocation: Keeping the position size at 1% reflects the high-risk nature of the trade, minimizing overall portfolio impact. Disclaimer This recommendation is for educational purposes only. Always consult your financial advisor before making any investment decisions. Stock trading involves risks, including the potential loss of capital. Ensure to evaluate your risk tolerance and conduct thorough research.
NYSE:VFCLong
by KSLBroking
Can Market Turbulence Create Future Innovation?In a dramatic turn of events that sent shockwaves through the pharmaceutical industry, Novo Nordisk's recent setback with its experimental obesity drug CagriSema presents a fascinating case study in market resilience and scientific progress. The company's stock plummeted 24% after trial results showed a 22.7% weight reduction efficacy, falling short of the anticipated 25% target. Yet, beneath this apparent disappointment lies a deeper story of pharmaceutical innovation and market adaptation. The obesity treatment landscape stands at a pivotal crossroads, with the market experiencing exponential growth from its modest beginnings to a staggering $24 billion industry in 2023. Novo Nordisk's journey, alongside competitor Eli Lilly, exemplifies how setbacks often catalyze breakthrough innovations. The CagriSema trial, involving 3,400 participants, represents a clinical study and a testament to the industry's commitment to addressing global health challenges. Looking ahead, this moment of market recalibration might well be remembered as a turning point in the evolution of obesity treatment. With projections suggesting a potential $200 billion market by the early 2030s, the current turbulence could drive even greater innovation and competition. The fact that only 57% of trial participants reached the highest CagriSema dose points to untapped potential and future opportunities for optimization, suggesting that today's apparent setback might pave the way for tomorrow's breakthroughs.
NYSE:NVOShort
by UDIS_View